Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.
Conditions
Interventions
inhaled ciclesonide (400maicrogram, twice daily, for three months)
Sponsors
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients with the definite diagnosis established when the clinicoradiologic findings were supported by the histologic evidence of noncaseating epitheloid cell granulomas and exclusion of other diseases capable of producing similar histologic or clinical features. 2. patients whose FEV1/FVC is under 80%, whose R5-R20 score is over 0.03, or whose WA% is over 55%. 3. patients over 20 years old who can give the documents which agree in participating this study
Exclusion criteria
Exclusion criteria: 1. patients with heart failure 2. patients with renal failure 3. patients with past hisotry of bronchial asthma 4. ex, or current smokers 5. patients with pulmonary disease except for pulmonary sarcoidosis 6. patients whose participations in this study are thought to be inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the influence of inhaled ciclesonide (400maicrogram, twice daily, for three months) on pulmonary function tests, impulse oscillometry system (IOS) and HRCT of pulmonary sarcoidosis patients. | — |
Countries
Japan
Contacts
Public ContactToshio Suzuki
Graduate School of Medicine, Chiba University, Chiba, Japan Department of Respirology
Outcome results
None listed